The Inflation Reduction Act is one of the Biden administration’s signature pieces of legislation, and its drug pricing provisions should really deliver significant improvements to America’s pharmaceutical marketplace. New policies will possible influence the base lines of drugmakers, trim margins for pharmacy advantage supervisors, and reduced out-of-pocket expenditures for Medicare […]
drugmakers
Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma. It also casts light on the profiteering methods of the drug industry’s price mediators – the pharmacy benefit managers, or PBMs […]